Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Short-term Investments (2016 - 2025)

Heron Therapeutics' Short-term Investments history spans 10 years, with the latest figure at $18.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments fell 46.29% year-over-year to $18.0 million; the TTM value through Dec 2025 reached $18.0 million, down 46.29%, while the annual FY2025 figure was $18.0 million, 46.29% down from the prior year.
  • Short-term Investments reached $18.0 million in Q4 2025 per HRTX's latest filing, up from $12.4 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $106.7 million in Q1 2021 to a low of $12.4 million in Q3 2025.
  • Average Short-term Investments over 5 years is $46.3 million, with a median of $44.2 million recorded in 2021.
  • Peak YoY movement for Short-term Investments: crashed 73.47% in 2021, then soared 147.5% in 2024.
  • A 5-year view of Short-term Investments shows it stood at $67.0 million in 2021, then increased by 3.65% to $69.5 million in 2022, then dropped by 25.55% to $51.7 million in 2023, then tumbled by 35.28% to $33.5 million in 2024, then tumbled by 46.29% to $18.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRTX's Short-term Investments are $18.0 million (Q4 2025), $12.4 million (Q3 2025), and $24.1 million (Q2 2025).